(Insulin detemir) is a hypoglycemic agent, an analogue of human long-acting insulin. The Levemir FlexPen is produced by the method of biotechnology of recombinant DNA using the strain Saccharomyces cerevisiae. It is a soluble basal analogue of human long-acting insulin with a flat action profile. The profile of the Levemir FlexPen preparation is significantly less variable than isophane-insulin and insulin glargine.
100% Original from the Russian CJSC Pharmaceft.
All packs are air tight sealed and expire up to 01.2022.
For doses of 0,2-0,4 UI/kg 50% the maximum effect of the drug occurs in the interval from 3-4 hours to 14 hours after use. The duration of action is up to 24 hours, depending on the dose, which provides the possibility of a single and twice daily use. After subcutaneous use, a pharmacodynamic response was observed proportional to the dose use. In long-term studies, low daily diurnal fluctuations in plasma glucose concentration were demonstrated in the treatment of patients with Levemir FlexPen as opposed to isophane-insulin.
Intended for subcutaneous use.
The dose and frequency of the Levemir FlexPen use is determined individually in each specific case.
Treatment in combination with oral hypoglycemic drugs, it is recommended to start once a day at a dose of 10UI/kg of body weight.The dose should be selected individually based on plasma glucose levels.
The MHRA and FDA has not evaluated or endorsed this product. Please consult your physician prior to using this or any other nutritional supplements or medications.
Store in dry place. Do not exceed storage temperature of 2-8 degrees Celcius. Do not freeze. Keep away from direct sunlight. Keep locked and away from children.
Ask us any questions about Levemir FlexPen.
|The purpose of the medication||Diabetes Treatment|